<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04812509</url>
  </required_header>
  <id_info>
    <org_study_id>MW032-2019-CP301</org_study_id>
    <nct_id>NCT04812509</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Parallel Controlled Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of Recombinant Human Anti RANKL Monoclonal Antibody Injection (MW032) and Denosumab (Xgeva®) in Subjects With Bone Metastases From Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mabwell (Shanghai) Bioscience Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mabwell (Shanghai) Bioscience Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, randomized, double-blind, parallel controlled Phase III clinical study to&#xD;
      evaluate the clinical efficacy and safety of MW032 and Xgeva® in patients with bone&#xD;
      metastases from solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is A multi-center, randomized, double-blind, parallel controlled Phase III clinical&#xD;
      trial.&#xD;
&#xD;
      The primary objective is to evaluate the clinical efficacy of MW032 and Xgeva® in patients&#xD;
      with bone metastases from solid tumors.&#xD;
&#xD;
      The secondary objective are to evaluate the clinical safety and immunogenicity of MW032 and&#xD;
      Xgeva® in patients with bone metastases from solid tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 20, 2020</start_date>
  <completion_date type="Anticipated">February 6, 2022</completion_date>
  <primary_completion_date type="Actual">April 29, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>uNTx/uCr</measure>
    <time_frame>from baseline to week 13</time_frame>
    <description>Compare MW032 and Xgeva® for percentage change in bone conversion index (BTM) - urinary type I collagen cross-linked peptide (uNTx) adjusted for urinary creatinine (uCr) in Chinese subjects with solid tumor bone metastasis (uNTx/uCr from baseline to week 13)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>uNTx/uCr</measure>
    <time_frame>from baseline to weeks 5,25,37 and 53</time_frame>
    <description>Compare the percentage change in MW032 and Xgeva® for bone conversion indicator uNTx/uCr among subjects with solid tumor metastasis (from baseline to weeks 5,25,37 and 53).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>S-BALP</measure>
    <time_frame>from baseline to weeks 5,13,25,37 and 53</time_frame>
    <description>Compare the changes of bone specific alkaline phosphatase (S-BALP) from baseline to weeks 5,13, 25,37 and 53.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SRE</measure>
    <time_frame>from baseline to week 53</time_frame>
    <description>SRE occurrence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">706</enrollment>
  <condition>Bone Metastases</condition>
  <arm_group>
    <arm_group_label>MW032</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MW032 injection(120mg) was administered subcutaneously once every 4 weeks for a maximum of 13 consecutive doses throughout the trial, according to the investigator's assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xgeva®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xgeva® injection(120mg) was administered subcutaneously every 4 weeks for a maximum of 13 cumulative doses throughout the trial,according to the investigator's assessment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MW032</intervention_name>
    <description>The active ingredient of MW032 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.</description>
    <arm_group_label>MW032</arm_group_label>
    <other_name>recombinant human anti-RANKL monoclonal antibody injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xgeva</intervention_name>
    <description>The active ingredient of Xgeva® is denosumab,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.</description>
    <arm_group_label>Xgeva®</arm_group_label>
    <other_name>Denosumab Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pathological confirmed malignant tumors (except hematological tumors);&#xD;
&#xD;
          2. Bone metastasis diagnosed by imaging (bone X-ray, CT scanning or magnetic resonance&#xD;
             scanning) or pathology (bone biopsy) can be examined within 3 months before signing&#xD;
             the informed consent,according to 《The expert consensus on clinical diagnosis and&#xD;
             treatment of bone metastases and bone related diseases of malignant tumors (2014)》；&#xD;
&#xD;
          3. No limited of gender,age ≥ 18 years old;&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2;&#xD;
&#xD;
          5. Estimated survival time was more than 6 months;&#xD;
&#xD;
          6. Subjects must have adequate organ function at baseline as defined below:① hematology:&#xD;
             neutrophils ≥ 1,500/mcL, platelets ≥ 75,000/mcL, hemoglobin ≥ 80 g / L; ② renal&#xD;
             function: creatinine (CR) clearance rate ≥ 30 ml / min; ③ Liver function: serum&#xD;
             aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were less than or&#xD;
             equal to 2.0 × upper normal limit (ULN) in subjects without liver metastasis; ALT and&#xD;
             AST were less than or equal to 5.0 × ULN in subjects with liver metastasis; serum&#xD;
             total bilirubin was less than or equal to 1.5 × ULN; ④ serum calcium (albumin&#xD;
             correction) was more than or equal to 2.0 mmol / L (8.0 mg / dl) but less than or&#xD;
             equal to 2.9 mmol / L (11.5 mg / dl). Note: calcium supplements should not be used at&#xD;
             least 8 hours before serum calcium determination in screening period;&#xD;
&#xD;
          7. Subjects has understood the nature and purpose of the study, as well as the research&#xD;
             procedure, and the subject has signed the written informed consent;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with diseases not suitable for the study,in the Investigator's opinion&#xD;
             (according to the subject's report or medical record review), such as:Other malignant&#xD;
             tumors (different from the malignant solid tumors required in this study protocol)&#xD;
             occurred within 3 years before enrollment, and in the active period;Other diseases&#xD;
             affecting bone metabolism, such as vitamin D deficiency rickets, osteomalacia and&#xD;
             primary osteoporosis, hyperparathyroidism, osteitis deformans, etc. (excluding&#xD;
             osteoporosis);Human immunodeficiency virus or Treponema pallidum infection;Unstable&#xD;
             liver disease, active period of hepatitis B virus or hepatitis C virus infection;Other&#xD;
             serious or unstable physical or mental disorders.&#xD;
&#xD;
          2. Brain metastasis.&#xD;
&#xD;
          3. Oral and dental diseases: previous or current evidence of osteomyelitis or necrosis of&#xD;
             the jaw; acute dental or mandibular diseases, need to be treated oral surgery; planned&#xD;
             invasive dental surgery; failed dental or oral surgery.&#xD;
&#xD;
          4. Subjects with bone metastases need radiotherapy or surgery.&#xD;
&#xD;
          5. Previous treatment with denosumab.&#xD;
&#xD;
          6. Patients who had received any kind of intravenous or oral bisphosphonates before&#xD;
             administration of the first study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fifth Medical Center of PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Denosumab</keyword>
  <keyword>Biosimilarity</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

